ArticleCureus2025
Role of Gastric Point-of-Care Ultrasound in Perioperative Management of Semaglutide.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Perioperative Management of Patients using GLP-1 Receptor Agonists Current Evidence, Risks, and Practical Recommendations-A Narrative Review.Turkish journal of anaesthesiology and reanimation · 2026Article
- Perioperative risks of glucagon-like peptide-1 receptor agonists and their implications in airway management using supraglottic airway devices.Anesthesia and pain medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Glucagon-like peptide-1 receptor agonists (GLP1-RAs) are used in the treatment of type 2 diabetes mellitus and obesity. A side effect of GLP1-RAs is delayed gastric emptying, which could increase the risk of pulmonary aspiration. This exploratory pilot study examines the use of ultrasound to identify high-risk patients taking GLP-1RAs before elective surgery. Methods A prospective study from July 2023 to February 2024 was conducted on patients who took their last weekly dose of semaglutide less than seven days before surgery. If preoperative gastric ultrasound revealed an empty stomach, surgery proceeded. Patients with residual gastric contents were rescheduled. Patient demographics, semaglutide dosage and timing, nil per os (NPO) time, and postoperative complications were reviewed. Statistical significance was set at p < 0.05. Results Twenty-five patients took their weekly semaglutide less than seven days before surgery. Twenty patients (80%) demonstrated empty stomachs on ultrasound and proceeded with surgery without complications. Gastric contents were found in five patients (20%), and surgery was rescheduled. Patients who took semaglutide one to three days before surgery were more likely to have residual gastric contents as compared to those who took semaglutide four to six days before surgery (p = 0.02). Discussion Gastric ultrasound is a useful tool that can prevent the cancellation of surgery for patients on semaglutide. Patients who took semaglutide within one to three days were more likely to have residual gastric contents compared to those who took it four to six days prior. Conclusion Preoperative gastric ultrasound can identify high-risk patients on semaglutide despite adequate NPO status.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.